Cell Therapy Durability Response Summit

Paid

The current generation of CAR-T approaches for hematological malignancies generate strong responses in cancer patients, but too often progression-free survival is less than 12 months. The next-generation allogeneic approaches may make these therapies more accessible to the patients who need them but have been hampered by poor in vivo persistence.

22-23 August 2022

Healthcare

3rd Annual Gene Therapy Comparability Summit

Paid

In the context of ever-important gene therapy scale-up to achieve commercial goals and mounting regulatory scrutiny, the 3rd Annual Gene Therapy Comparability Summit is the only event focused on comparability of gene therapy.

28-30 March 2023

Healthcare